Deutsche Bank analyst Dan Leonard raised his price target for Thermo Fisher to $300 from $275 saying the acquisition of Brammer Bio fills the gap in its contract services offering. The analyst believes Thermo Fisher can continue to exceed market growth rates “despite uniquely challenging comps.” He says the acquisition supports his thesis and keeps a Buy rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.